Strategic partnerships Puma Biotechnology has a history of collaboration and licensing arrangements for its cancer drug alisertib, including partnerships with Takeda and exclusive license agreements. This suggests openness to BD opportunities with large pharma and specialty biotech firms for co-development, regional licensing, or potential in-licensing discussions.

Aurora kinase potential Alisertib, a selective aurora kinase A inhibitor, remains a focal product with ongoing development and commercialization rights. This presents a clear up-sell or expansion path for oncology-focused CROs, contract manufacturers, and digital health platforms that support targeted cancer therapies and companion diagnostics.

HER2+ focus The company emphasizes benefits for the HER2+ breast cancer community, indicating ongoing market need in this niche. Opportunities exist to offer diagnostic collaborations, real-world evidence studies, or patient support programs that align with HER2+ patient pathways and payer strategies.

Investor interest Active participation in investor conferences signals ongoing fundraising and market visibility. This environment can be leveraged for outreach to biotech-focused investors, strategic corporate development teams, and potential co-development or acquisition discussions tied to late-stage or near-market assets.

Security and data Past data breach investigations highlight potential cybersecurity and risk mitigation needs. Offering enterprise security assessments, compliance consulting, or data protection solutions could align with their tech stack and risk posture as they scale clinical and regulatory activities.